A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To study the safety and effectiveness of foscarnet in the treatment of AIDS patients who have
active infection with cytomegalovirus (CMV) that is causing inflammation of the retina
(retinitis). In addition, these patients cannot be treated with ganciclovir (DHPG) because of
its toxic effect on the body's blood-forming cells or because white blood cell or platelet
counts were too low.
CMV is a common virus, which can cause blindness and death in AIDS patients. Previous studies
demonstrate that foscarnet has been effective in both AIDS and non-AIDS patients with CMV
infection. Although treatment with ganciclovir (DHPG) is also effective, a significant
toxicity leading to dose-limiting neutropenia (low white blood cell count) in one third of
treated patients has been associated with the drug. Based on the serious nature of CMV
retinitis and the lack of alternative drug therapies for DHPG-sensitive patients, the present
study will evaluate the safety and efficacy of intravenous (IV) foscarnet in AIDS patients
with CMV retinitis.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)